Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Rheumatoid factor appearance after tocilizumab treatment seems to predict bad therapeutical response in rheumatoid arthritis.

× No keyword cloud information.

9 in total

1. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy.

Authors: Leen De Rycke; Elli Kruithof; Nancy Van Damme; Ilse E A Hoffman; Nancy Van den Bossche; Filip Van den Bosch; Eric M Veys; Filip De Keyser
Journal: Arthritis Rheum Date: 2003-04

2. Autoantibodies in patients with psoriatic arthritis on anti-TNFα therapy.

Authors: Vilma S Trindade Viana; Jozélio Freire de Carvalho; Júlio César Bertacini de Moraes; Carla Gonçalves Schain Saad; Ana Cristina de Medeiros Ribeiro; Célio Gonçalves; Cleonice Bueno; Margarete B Vendramini; Eloísa Bonfá
Journal: Rev Bras Reumatol Date: 2010 May-Jun

Review 3. Laboratory changes on anti-tumor necrosis factor treatment in rheumatoid arthritis.

Authors: Maria Ziolkowska; Wlodzimierz Maslinski
Journal: Curr Opin Rheumatol Date: 2003-05 Impact factor: 5.006

4. In rheumatoid arthritis patients treated with tocilizumab, the rate of clinical disease activity index (CDAI) remission at 24 weeks is superior in those with higher titers of IgM-rheumatoid factor at baseline.

Authors: Shin-Ya Kawashiri; Atsushi Kawakami; Naoki Iwamoto; Keita Fujikawa; Toshiyuki Aramaki; Mami Tamai; Satoshi Yamasaki; Hideki Nakamura; Tomoki Origuchi; Yukitaka Ueki; Kiyoshi Migita; Akinari Mizokami; Kiyoshi Aoyagi; Katsumi Eguchi
Journal: Mod Rheumatol Date: 2011-01-15 Impact factor: 3.023

5. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis.

Authors: Alexandra Bruns; Pascale Nicaise-Roland; Gilles Hayem; Elisabeth Palazzo; Philippe Dieudé; Sabine Grootenboer-Mignot; Sylvie Chollet-Martin; Olivier Meyer
Journal: Joint Bone Spine Date: 2009-02-08 Impact factor: 4.929

6. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement.

Authors: C Alessandri; M Bombardieri; N Papa; M Cinquini; L Magrini; A Tincani; G Valesini
Journal: Ann Rheum Dis Date: 2004-10 Impact factor: 19.103

7. Development of antinuclear antibodies and its clinical impact in patients with Crohn's disease treated with chimeric monoclonal anti-TNFalpha antibodies (infliximab).

Authors: Esther Garcia-Planella; Eugeni Domènech; Maria Esteve-Comas; Isabel Bernal; Eduard Cabré; Jaume Boix; Miquel A Gassull
Journal: Eur J Gastroenterol Hepatol Date: 2003-04 Impact factor: 2.566

Review 8. Autoimmune diseases induced by TNF-targeted therapies.

Authors: Manuel Ramos-Casals; Pilar Brito-Zerón; Maria-Jose Soto; Maria-Jose Cuadrado; Munther A Khamashta
Journal: Best Pract Res Clin Rheumatol Date: 2008-10 Impact factor: 4.098

9. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment.

Authors: Francesca Bobbio-Pallavicini; Claudia Alpini; Roberto Caporali; Stefano Avalle; Serena Bugatti; Carlomaurizio Montecucco
Journal: Arthritis Res Ther Date: 2004-04-26 Impact factor: 5.156

9 in total

2 in total

Review 1. Cross-reactive and pre-existing antibodies to therapeutic antibodies--Effects on treatment and immunogenicity.

Authors: Karin A van Schie; Gerrit-Jan Wolbink; Theo Rispens
Journal: MAbs Date: 2015 Impact factor: 5.857

Review 2. Rheumatoid factors: clinical applications.

Authors: Francesca Ingegnoli; Roberto Castelli; Roberta Gualtierotti
Journal: Dis Markers Date: 2013-11-13 Impact factor: 3.434

2 in total